Retension Pharmaceuticals (RTSN) Director M Buys $120K of Stock
Franklin M Berger, a director at Retension Pharmaceuticals, purchased 10,000 shares on October 13, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Berger Franklin M, Director at Retension Pharmaceuticals, Inc. ($RTSN), bought 10,000 shares at an average price of $12, worth about $120,000, on October 13, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RTSN is up 21.0% to date (from the $11.63 close on Oct 13, 2026).
RTSN
Retension Pharmaceuticals, Inc.
Key Points
- Franklin M Berger bought 10,000 shares of Retension Pharmaceuticals at $12.00 each on October 13, 2026, totaling $120,000.
- The stock recently traded around $13.27, which is 15.7% above its 50-day and 200-day moving averages.
- CEO Eric Keller also bought 20,800 shares on the same day, reflecting strong insider confidence.
Get $RTSN trade alerts by text
We text you when insiders, Congress or big funds trade $RTSN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Retension Pharmaceuticals, Inc. alert may contain errors. Disclosures
Franklin M Berger, a director at Retension Pharmaceuticals, Inc. (NasdaqCM: RTSN), bought 10,000 shares on October 13, 2026, at a price of $12.00 each. This purchase totals $120,000. The trade was not planned under a Rule 10b5-1 arrangement.
Berger Franklin M vs. the S&P 500
Hypothetical returns from Berger Franklin M's disclosed trades, not real profit or advice. How we model this.
Inside Berger Franklin M's Trade
Berger's acquisition adds to the confidence shown by insiders at Retension Pharmaceuticals. On the same day, CEO Eric Keller bought 20,800 shares at the same price of $12.00, totaling $249,600. This move suggests a strong belief in the company's future, especially in the context of its focus on developing treatments for hypertension and cardiovascular diseases.
Retension Pharmaceuticals, Inc. Stock Up 8.6%
As of October 16, 2026, Retension Pharmaceuticals was recently trading around $13.27. This price is about 15.7% above both its 50-day and 200-day moving averages, which could suggest positive momentum. However, it remains about 11.4% below its 52-week high of $14.97.
Recent Earnings
Retension Pharmaceuticals does not currently have a meaningful P/E ratio due to its negative trailing twelve-month EPS of -$2.61. The company has not yet announced its next earnings date, but its financials indicate it is still in the clinical stage of development.
Insider Buying and Selling at Retension Pharmaceuticals, Inc.
In addition to Berger's purchase, CEO Eric Keller also made a significant buy on October 13, 2026. Keller acquired 20,800 shares at $12.00 each, totaling $249,600. Both trades reflect a strong commitment from the management team to the company's prospects.
Analysts Set New Price Targets
There are currently no analyst ratings or price targets for Retension Pharmaceuticals, reflecting the early-stage nature of the company and its limited coverage in the market.
About Retension Pharmaceuticals
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Falls Church, Virginia. It focuses on developing innovative treatments for hypertension and other cardiovascular issues. The company is working on RTN-001, a small molecule designed to help lower blood pressure by enhancing nitric oxide signaling.
Bottom Line
Investors will be keeping an eye on further insider trades and any upcoming announcements from Retension Pharmaceuticals. The company remains in a development phase, and its next earnings date has not yet been revealed. Berger's and Keller's recent purchases are noteworthy signals of their confidence in the company's future potential.
Related Filing Alerts
Source: Berger Franklin M's Form 4 filing on $RTSN (Oct 13, 2026). Find the original filing: RTSN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts